These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17569308)

  • 21. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure.
    Trikas A; Antoniades C; Latsios G; Vasiliadou K; Karamitros I; Tousoulis D; Tentolouris C; Stefanadis C
    Eur J Heart Fail; 2006 Dec; 8(8):804-9. PubMed ID: 16713737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ca2+ sensitizers].
    Endoh M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):859-67. PubMed ID: 10771644
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan.
    Kamath SR; Jaykumar I; Matha S
    Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
    [No Abstract]   [Full Text] [Related]  

  • 29. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 32. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
    Sato N
    Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
    [No Abstract]   [Full Text] [Related]  

  • 34. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
    Caimmi PP; Grossini E; Molinari C; Vacca G; Teodori G
    Ann Thorac Surg; 2006 Nov; 82(5):e33-4. PubMed ID: 17062205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.
    Ukkonen H; Saraste M; Akkila J; Knuuti MJ; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 1997 May; 61(5):596-607. PubMed ID: 9164421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripartum cardiomyopathy: a new successful setting for levosimendan.
    Benezet-Mazuecos J; de la Hera J
    Int J Cardiol; 2008 Jan; 123(3):346-7. PubMed ID: 17324479
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.